The Consumer Directed Health Care Conference, being held this week in Washington, shows the growing interest in this new movement. More than 1,000 people registered for the conference, and many of the attendees are leaders with top companies from outside the health sector, such as Microsoft, Intel, General Electric, Fidelity Investments, and JP Morgan, as well as a long list of companies from … [Read more...] about Change is Coming
Don't Monkey With Seniors' Medicare Savings
Seniors across the country are trying to understand the new Medicare drug benefit. They have a strong incentive to get up to speed: Once the program launches in January, it will cut individual prescription drug bills by as much as two thirds. The innovative drug benefit, created by the Medicare Modernization Act of 2003, or MMA, combines generous public spending with real competition among … [Read more...] about Don't Monkey With Seniors' Medicare Savings
How Europe's Drug Industry Lost Its Mojo
An idea gaining currency on both sides of the aisle proposes that the U.S. government step in and "negotiate" drug prices for Medicare recipients. Lawmakers should stop and consider the fate of the pharmaceutical industry in Europe, where this practice is widespread, before they go down this misguided path. Medicare-eligible senior citizens consume about 45 percent of all … [Read more...] about How Europe's Drug Industry Lost Its Mojo
Don’t Monkey With Seniors’ Medicare Savings
Seniors across the country are trying to understand the new Medicare drug benefit. They have a strong incentive to get up to speed: Once the program launches in January, it will cut individual prescription drug bills by as much as two thirds. The innovative drug benefit, created by the Medicare Modernization Act of 2003, or MMA, combines generous public spending with real competition among … [Read more...] about Don’t Monkey With Seniors’ Medicare Savings
How Europe’s Drug Industry Lost Its Mojo
An idea gaining currency on both sides of the aisle proposes that the U.S. government step in and "negotiate" drug prices for Medicare recipients. Lawmakers should stop and consider the fate of the pharmaceutical industry in Europe, where this practice is widespread, before they go down this misguided path. Medicare-eligible senior citizens consume about 45 percent of all … [Read more...] about How Europe’s Drug Industry Lost Its Mojo
Growing and Collapsing
The Medicaid program finances health coverage for one in six Americans ? 52 million people. This joint federal-state program will cost more than $300 billion this year and is growing rapidly. … [Read more...] about Growing and Collapsing
Growing and Collapsing
The Medicaid program finances health coverage for one in six Americans ? 52 million people. This joint federal-state program will cost more than $300 billion this year and is growing rapidly. … [Read more...] about Growing and Collapsing
Too Many Choices!
As you will recall, the Galen Institute worked hard, along with AEI and Heritage, several years ago to promote an idea for a Medicare prescription drug benefit that would be based upon a funded drug discount card coupled with insurance coverage for large drug expenses. Our idea was adopted in part with the enactment of the temporary drug discount card. The Medicare Modernization Act created a … [Read more...] about Too Many Choices!